Fig. 3
Effects of an LPAR3 antagonist and agonist on EPO expression in hypoxic mouse kidneys. A-B Renal EPO mRNA levels (A) and plasma EPO levels (B) in the WT mice treated with Ki16425 followed by hypoxia exposure (8% O2, 6 h). C-D Renal EPO mRNA levels (C) and plasma EPO levels (D) in the WT mice subjected to 2S-OMPT treatment followed by hypoxia exposure (8% O2, 6 h). n = 6 at each time point. The p value was determined by 2-way analysis of variance (ANOVA) followed by a post hoc test. **p < 0.01, ***p < 0.001, ****p < 0.0001 relative to the isogenic normoxia control; #p < 0.05, ##p < 0.01 between the two genotype groups; mean ± SEM